

# **UNIVERSITI PUTRA MALAYSIA**

# SYNERGISTIC EFFECT OF BIFIDOBACTERIUM PSEUDOCATENULATUM AND FRUCTOOLIGOSACCHARIDES AGAINST ESCHERICHIA COLI

LIM LONG CHANG.

FSMB 2004 12



## SYNERGISTIC EFFECT OF *BIFIDOBACTERIUM PSEUDOCATENULATUM* AND FRUCTOOLIGOSACCHARIDES AGAINST *ESCHERICHIA COLI*

By

## LIM LONG CHANG

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Master of Science

April 2004



•

Abstract of thesis presented to the Senate of Universiti Putra Malaysia in fulfilment of the requirements for the degree of Master of Science

### SYNERGISTIC EFFECT OF *BIFIDOBACTERIUM PSEUDOCATENULATUM* AND FRUCTOOLIGOSACCHARIDES AGAINST *ESCHERICHIA COLI*

By

### LIM LONG CHANG

#### April 2004

#### Chairman: Associate Professor Mohd Yazid Manap, Ph.D.

Faculty : Food Science and Biotechnology

8 wild type strains of *Bifidobacterium pseudocatenulatum* and 4 commercial strains (*B. pseudocatenulatum* JCM 1200, *B. infantis* ATCC 15698, *B. breve* ATCC 26720 *and B. longum* BB536) were screened for inulinase activity on modified PY-O and PY-I agar. Wild type *B. pseudocatenulatum* F117 and reference *B. pseudocatenulatum* JCM 1200 were determined to have the highest inulinase activity. This activity was apparently higher on PY-O agar in comparison to PY-I agar. In batch cultivation, growth of *B. pseudocatenulatum* F117 was enhanced in PY-O medium (0.38 h<sup>-1</sup> and 2.64 x 10<sup>8</sup> cfu/mL), compared to PY-G (0.48 h<sup>-1</sup> and 5.45 x 10<sup>8</sup> cfu/mL) and PY-I medium (0.20 h<sup>-1</sup> and 1.70 x 10<sup>8</sup> cfu/mL) from the respective, initial specific growth rate and maximum growth. Acetic, lactic and formic acid production was also found to be relatively higher in PY-O medium (38.60 mM; 37.48 mM; 7.37 mM) compared to PY-G medium (11.95 mM; 22.77 mM; 5.91 mM) or PY-I medium (12.34 mM; 19.73 mM; 0 mM). In therapeutic



study, the antagonistic effect against E. coli V157 by B. pseudocatenulatum F117 was contributed by pH lowering of the growth medium. This effect was especially intensified at pH below 5.0. Antagonistic effect found in PY-O medium was greater compared to that of PY-G medium. The kinetics of antagonistic effect could be divided into two apparent phases. It was the condition before (first phase) and after (second phase) B. pseudocatenulatum F117 to achieve the maximum growth (10<sup>9</sup> cfu/mL), with relatively intense antagonistic effect at second phase. Organic acid was highly produced at second phase (PY-G medium: 45.57±8.99 mM; PY-O medium: 61.54±11.92 mM) rather than first phase (PY-G medium: 25.59±3.16; PY-O medium: 30.46±7.21 mM) implicative of the importance of probiotic concentration for effective antagonism. Oligofructose was found to be able to stimulate the growth of B. pseudocatenulatum F117 and consequently shorten the time for the maximum growth to achieve, from 18 hr in PY-G medium to 12 hr in PY-O medium. Besides, lactic acid production was initiated 6 hr earlier in PY-O medium than to PY-G medium, which could be an added inhibitory advantage. With low bifidobacteria dose  $(10^5 \text{ cfu/mL})$ , the antagonistic effect displayed was quite identical to a higher dose (10<sup>8</sup> cfu/mL) employed. B. pseudocatenulatum F117 was found to obtain the maximum growth in 18 hr for the both trial doses in either growth medium. In prophylactic study, PY-O medium could not be observed to further enhance the antagonistic effect in PY-G medium. E. coli V157 (10<sup>8</sup> cfu/mL) was unable to sustain and multiply to a higher population but decreased in numbers in either growth mediums. Finally, a higher oligofructose concentration (1.0 %) was shown to dramatically improve the antagonistic effect as compared to the lower



concentration (0.5 %) used, in both therapeutic and prophylactic study. This effect was again due to an even higher amount of organic acids produced.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan ijazah Master Sains

### KESAN SINERGISTIK DI ANTARA *BIFIDOBACTERIUM PSEUDOCATENULATUM* DAN OLIGOFRUKTOSA TERHADAP *ESCHERICHIA COLI*

Oleh

### LIM LONG CHANG

#### April 2004

### Pengerusi: Profesor Madya Mohd Yazid Manap, Ph.D.

Fakulti : Sains Makanan dan Bioteknologi

8 stren liar *Bifidobacterium pseudocatenulatum* dan 4 stren *komersial (B. pseudocatenulatum* JCM 1200, *B. infantis* ATCC 15698, *B. breve* ATCC 26720 dan *B. longum* BB536) disaring untuk aktiviti inulinase ke atas agar gubahan PY-O dan PY-I. Stren liar *B. pseudocatenulatum* F117 dan kawalan *B. pseudocatenulatum* JCM 1200 didapati memperoleh aktiviti inulinase yang tertinggi. Aktiviti tersebut adalah lebih ketara tinggi pada agar PY-O dibanding dengan agar PY-I. Dalam pengkulturan tertutup, pertumbuhan *B. pseudocatenulatum* F117 dipertingkatkan dalam media PY-O (0.38 h<sup>-1</sup> and 2.64 x 10<sup>8</sup> cfu/mL) berbanding dengan media PY-G (0.48 h<sup>-1</sup> and 5.45 x 10<sup>8</sup> cfu/mL) dan PY-I (0.20 h<sup>-1</sup> and 1.70 x 10<sup>8</sup> cfu/mL) dari segi kadar pertumbuhan spesifik awal dan pertumbuhan maksimum masing-masing. Penghasilan asid asitik, laktik dan formik juga didapati lebih tinggi dalam media PY-O (38.60 mM; 37.48 mM; 7.37 mM) dibanding dengan media PY-G (11.95 mM; 22.77 mM; 5.91 mM) mahupun media PY-I (12.34 mM; 19.73 mM; 0 mM). Dalam



kajian pemulihan, kesan antagonistik terhadap E. coli V157 daripada B. pseudocatenulatum F117 adalah disebabkan oleh penurunan pH media pertumbuhan. Kesan ini menjadi lebih hebat di bawah pH 5.0. Kesan antagonistik di dalam media PY-O adalah lebih hebat dibandingkan di dalam media PY-G. Kinetics dalam kesan antagonistik dapat dibahagikan kepada dua fasa yang jelas. Ini adalah keadaan sebelum (fasa pertama) dan selepas (fasa kedua) B. pseudocatenulatum F117 mencapai pertumbuhan maksimumnya (10<sup>9</sup> cfu/mL), di mana kesan antagonistik yang lebih hebat berlaku pada fasa yang kedua. Asid organik banyak dihasilkan pada fasa kedua (media PY-G: 45.57±8.99 mM; media PY-O: 61.54±11.92 mM) berbanding dengan fasa pertama (media PY-G: 25.59±3.16; media PY-O: 30.46±7.21 mM), justerunya mengimplikasikan kepentingan kandungan probiotik untuk antagonisma yang berkesan. Oligofruktosa didapati merangsangkan pertumbuhan B. pseudocatenulatum F117 dan seterusnya mengurangkan tempoh untuk mencapai pertumbuhan maksimumnya (10<sup>9</sup> cfu/mL), daripada 18 j dalam media PY-G kepada 12 j dalam media PY-O. Di samping itu, penghasilan asid laktik bermula 6 j lebih awal dalam media PY-O daripada dalam media PY-G, kemungkinan besar menjadi kebaikan tambahan faktor perencatan. Pada dos bifidobakteria yang rendah (10<sup>5</sup> cfu/mL), kesan antagonistik yang dihasilkan adalah agak sama dengan dos yang tinggi (10<sup>8</sup> cfu/mL) digunakan. B. pseudocatenulatum F117 didapati mencapai pertumbuhan maksimum dalam 18 j untuk kedua-dua dos dalam mana-mana media pertumbuhan. Dalam kajian pencegahan, media PY-O didapati tidak meningkatkan kesan antagonistik lagi sepertimana yang diperhatikan dalam media PY-G. E. coli (10<sup>8</sup> cfu/mL) tidak dapat mengekal mahupun



membangun kepada populasi yang lebih tinggi tetapi berkurangan dalam bilangannya. Akhirnya, kepekatan oligofruktosa yang tinggi (1 %) didapati menghasilkan kesan antagonistik yang lebih hebat daripda kepekatan rendahnya (0.5 %) dalam kedua-duanya kajian pemulihan dan pencegahan. Kesan ini disebabkan oleh penghasilan asid organik yang lebih tinggi lagi.



#### ACKNOWLEDGEMENTS

First of all, please let me ask for forgiveness upon all the mistakes done inadvertently in thoughts, words or actions to everyone along my way in carrying out these experiments. Sorry if I have not fulfilled the expectation that you all wish for. I sincerely repent myself, Namo Amituofo!

Next, may I extend my heartfelt gratitude to my chairperson of supervisory committee, Assoc. Prof. Dr. Mohd Yazid Abd Manap, for his invaluable advises and guidance throughout the course of my study. My thanks also to Assoc. Prof. Dr. Arbakariya Ariff and Assoc. Prof. Dr. Sharifah Kharidah, being my co-supervisors for their patience and endurance with my progress.

Also not forget to forward a special thank to Mr. Halim for helping me out in the HPLC analysis. Thanks to my senior, Dr. Shuhaimi for his voluntarily helps in familiarizing me the fundamental laboratory skills before I can help myself very well later. My deepest thanks must go equally to the rest of all the faculty staffs who accompanied me like a happy family that help to put away my homesickness here.

Finally, but not least, I wish to call upon my grateful appreciation to these peoples who cheered me up always when I encountered failure and disappointments: Lovely Miss Levina, Anis, Leng Choo, Siew Eim, Sek Yee, Hooi Ling, Wendy, Santhy, brother Sohail and both my parents. Thanks a lot! Amituofo.



I certify that an Examination Committee met on 22<sup>nd</sup> April 2004 to conduct the final examination of Lim Long Chang on his Master of Science thesis entitled "Synergistic Effect of *Bifidobacterium pseudocatenulatum* and Fructooligosaccharides against *Escherichia coli*" in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the candidate be awarded the relevant degree. Members of the Examination Committee are as follows:

### Zaiton Hassan, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Chairman)

### Mohd Yazid Abd Manap, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Member)

### Arbakariya Ariff, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Member)

### Sharifah Kharidah Syed Muhammad, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Member)

GULAM RUSUL RAHMAT ALI, Ph.D. Professor/Deputy Dean School of Graduate Studies Universiti Putra Malaysia

Date: 13 AUG 2004



This thesis submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirement for the degree of Master of Science. The members of Supervisory Committee are as follows:

### Mohd Yazid Abd Manap, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Chairman)

Arbakariya Ariff, Ph.D. Associate Professor

Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Member)

### Sharifah Kharidah Syed Muhammad, Ph.D.

Associate Professor Faculty of Food Science and Biotechnology Universiti Putra Malaysia (Member)

eij

AINI IDERIS, Ph.D. Professor/Dean School of Graduate Studies Universiti Putra Malaysia

Date: 0 8 SEP 2004



## DECLARATION

I hereby declare that the thesis is based on my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously or concurrently submitted for any other degree at UPM or other institution.

loch

LIM LONG CHANG

Date: 27/06/2004



## **TABLE OF CONTENTS**

	Page
ABSTRACT	ii
ABSTRAK	v
ACKNOWLEDGEMENTS	viii
APPROVAL	ix
DECLARATION	xi
LIST OF TABLES	xiv
LIST OF FIGURES	xvi
LIST OF PLATES	xviii
LIST OF ABBREVIATIONS	xix

## CHAPTER

1	INTI	RODUCTION	1
2	LITI	ERATURE REVIEW	
	2.1	The Gastrointestinal Tract (GIT) as an Ecosystem	5
		2.1.1 Gut Microflora	7
	2.2	Characteristics of Fermentation in the Human Colon	10
	2.3	Bowel Health and Related Diseases	13
	2.4	Introducing Probiotic and Prebiotic	16
		2.4.1 Probiotic	17
		2.4.1.1 Properties and Proposed Mechanism	
		of Action of Probiotic	19
		2.4.2. The Evolution of Bifidobacteria in Human	20
		2.4.2.1 Bifidobacteria and its Clinical Efficacy	
		to Diseases	22
		2.4.3 An Alternative Approach to Probiotic-Prebiotic	24
		2.4.3.1 Fructooligosaccharide (FOS) as Prebiotic	27
		2.4.3.2 The Synbiotic Approach	31
2.5	Continuous Flow Culture (CFC) As a Tool to Study the		
		Bacteria Interaction and Fermentation in the Gut	33
		2.5.1 Theory of CFC	34
	2.6	Kinetic of Cell Growth	36
3	MAT	FERIALS AND METHODS	
	3.1	Bacterial Strains	39
	3.2	Oligosaccharides	39
	3.3	Inulinase Activity Screening	40
	3.4	Inhibitory Activity of B. pseudocatenulatum F117	
		and JCM 1200 against E. coli V157	40



	3.5	Bioreactor Setting	41			
	3.6	3.6 Batch Cultivation				
	3.7	Determination of Flow Rate (F) in Continuous Flow Culture	42			
	3.8	Therapeutic Study	43			
		3.8.1 Preparation of <i>B. pseudocatenulatum</i> F117 Dose	43			
		3.8.2 The Parameters in the Interaction	44			
	3.9	Prophylactic Study	46			
		3.9.1 Preparation of <i>E. coli</i> V157 Dose	46			
		3.9.2 The Parameters in the Interaction	46			
	3.10	Mathematical Calculation	47			
	3.11	3.11 Organic Acids Analyses				
		3.11.1 Chromatography System and Operating Conditions	49			
		3.11.2 Reagents	50			
		3.11.3 Sample Preparation	50			
iv.	RES	ULTS AND DISCUSSION				
	4.1	Inulinase Activity of Bifidobacterium spp.	51			
	4.2	Inhibitory Activity of B. pseudocatenulatum F117 and				
		JCM 1200 against E. coli V157	59			
	4.3	Batch cultivation	61			
		4.3.1 Growth of <i>B. pseudocatenulatum</i> F117	61			
		4.3.2 Growth of <i>E. coli</i> V157	67			
		4.3.3 Determination of Flow Rate in Continuous Flow Culture	70			
	4.4	Therapeutic Study	74			
		4.4.1 Effect of Constant pH	74			
		4.4.2 High Bifidobacteria Dose (10 <sup>8</sup> cfu/mL)	77			
		4.4.2.1 Glucose (0.5 %) as Carbon Source	77			
		4.4.2.2 Oligofructose (0.5 %) as Carbon Source	85			
		4.4.3 Low Bifidobacteria Dose (10 <sup>5</sup> cfu/mL)	95			
		4.4.3.1 Glucose (0.5 %) as Carbon Source	95			
		4.4.3.2 Oligofructose (0.5 %) as Carbon Source	99			
		4.4.3.3 High Oligofructose Concentration (1.0 %)	105			
	4.5	Prophylactic Study	113			
		4.5.1 Glucose (0.5 %) as Carbon Source	113			
		4.5.2 Oligofructose (0.5 %) as Carbon Source	116			
		4.5.3 Higher Oligofructose Concentration (1.0%)	120			
v.	CON	CLUSIONS	129			
	BIBL	LIOGRAPHY	132			
	APPE	ENDICES	150			
	BIOI	BIODATA OF THE AUTHOR				



# LIST OF TABLES

Table		Page
1	Screening of <i>Bifidobacterium</i> spp. for inulinase activity using oligofructose (PY-O) and inulin (PY-I) fortified agar	52
2	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (high dose: 10 <sup>8</sup> cfu/mL) into the continuous culture, with 0.5 % glucose PY-G medium as growth substrate, in pH monitored condition.	76
3	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (high dose: 10 <sup>8</sup> cfu/mL) into the continuous culture, with 0.5 % glucose PY-G medium as growth substrate, in pH unmonitored condition.	79
4	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (high dose: 10 <sup>8</sup> cfu/mL) into the continuous culture, with 0.5 % oligofructose PY-O medium as growth substrate, in pH unmonitored condition.	87
5	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (low dose: 10 <sup>5</sup> cfu/mL) into the continuous culture, with 0.5 % glucose PY-G medium as growth substrate, in pH unmonitored condition.	97
6	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (low dose: 10 <sup>5</sup> cfu/mL) into the continuous culture, with 0.5 % oligofructose PY-O medium as growth substrate, in pH unmonitored condition.	101
7	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>B. pseudocatenulatum</i> F117 (low dose: 10 <sup>5</sup> cfu/mL) into the continuous culture, with 1.0 % oligofructose PY-O medium as growth substrate, in pH unmonitored condition.	107
8	Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of <i>E. coli</i> V157 (10 <sup>8</sup> cfu/mL) into the continuous culture, with 0.5 % glucose PY-G medium as growth substrate, in pH unmonitored condition.	115



xiv



- 9 Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of *E. coli* V157 (10<sup>8</sup> cfu/mL) into the continuous culture, with 0.5 % oligofructose PY-O medium as growth substrate, in pH unmonitored condition. 119
- 10 Specific growth rate ( $\mu$ ) of the individual species during interaction after the inoculation of *E. coli* V157 (10<sup>8</sup> cfu/mL) into the continuous culture, with 1.0 % oligofructose PY-O medium as growth substrate, in pH unmonitored condition.





# LIST OF FIGURES

Figure	2	Page
1	Increase in the mucosal surface by folding (Holzapfel et al., 1998)	5
2	Monomer of FOS or 1-kestose (GF2)	28
3.	Cell balance for a single stage bioreactor system	36
4.	The bacterial cell, substrate concentrations at different points are represented by X and S respectively in a single stage bioreactor system	49
5	(a) Growth of <i>B. pseudocatenulatum</i> F117 using different carbohydrates as substrate in the batch cultivation; and (b) the individual specific growth rate ( $\mu$ ) during fermentation as represented by the slope of the curve	62
6	Organic acids production by the batch cultivation of $B$ . pseudocatenulatum F117 in (a) PY-G, (b) PY-O, and (c) PY-I medium	66
7	(a) Growth of <i>E. coli</i> V157 using different carbohydrates as substrate in the batch cultivation; and (b) the individual specific growth rate ( $\mu$ ) during fermentation as represented by the slope of the curve	68
8	Determination of $\mu_m$ of <i>B. pseudocatenulatum</i> F117 in three different carbon mediums using logistic model equation. (a) PY-G medium (b) PY-O medium (c) PY-I medium	71
9	Determination of $\mu_m$ of <i>E. coli</i> V157 in three different carbon mediums using logistic model equation. (a) PY-G medium (b) PY-O medium (c) PY-I medium	72
10	(a) Therapeutics study on the antagonism of <i>B. pseudocatenulatum</i> F117 ( $10^8$ cfu/ml) against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % glucose PY-G medium under pH monitored condition	75
11	(a) Therapeutic study on the antagonism of <i>B. pseudocatenulatum</i> F117 $(10^8 \text{ cfu/ml})$ against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % glucose PY-G medium under pH monitored condition	78





12	(a) Therapeutic study on the antagonism of <i>B. pseudocatenulatum</i> F117 $(10^8 \text{ cfu/ml})$ against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % oligofructose PY-O medium under pH unmonitored condition	86
13	Specific growth rate ( $\mu$ ) of <i>E. coli</i> V157 during interaction with high dose (10 <sup>8</sup> cfu/mL) <i>B. pseudocatenulatum</i> F117 in the continuous system with different conditions applied.	88
14	(a) Therapeutic study on the antagonism of <i>B. pseudocatenulatum</i> F117 $(10^5 \text{ cfu/ml})$ against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % oligofructose PY-G medium under pH unmonitored condition	96
15	Therapeutic study on the antagonism of <i>B. pseudocatenulatum</i> F117 $(10^5 \text{ cfu/mL})$ against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % oligofructose PY-O medium under pH unmonitored condition	100
16	Therapeutic study on the antagonism of <i>B. pseudocatenulatum</i> F117 $(10^5 \text{ cfu/ml})$ against <i>E. coli</i> V157; and (b) organic acids production in 1.0 % oligofructose PY-O medium under pH unmonitored condition	106
17	Specific growth rate ( $\mu$ ) of <i>E. coli</i> V157 during interaction with low dose (10 <sup>5</sup> cfu/mL) <i>B. pseudocatenulatum</i> F117 in the continuous system with different conditions applied	108
18	(a) Prophylactic study on the antagonism of <i>B. pseudocatenulatum</i> F117 against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % glucose PY-G medium under pH unmonitored condition	114
19	(a) Prophylactic study on the antagonism of <i>B. pseudocatenulatum</i> F117 against <i>E. coli</i> V157; and (b) organic acids production in 0.5 % oligofructose PY-O medium under pH unmonitored condition	117
20	(a) Prophylactic study on the antagonism of <i>B. pseudocatenulatum</i> F117 against <i>E. coli</i> V157; and (b) organic acids production in $1.0 \%$ oligofructose PY-O medium under pH unmonitored condition	121



## LIST OF PLATES

Plate		Page
1	Bioreactor settings for (a) batch and (b) continuous cultivation	41
2	Inulinase activity of <i>Bifidobacterium</i> spp. on (a) PY-O agar and (b) PY-I agar with bromecresol purple as indicator	53
3	Low acid production of <i>B. pseudocatanulatum</i> F117 on PY-G (glucose fortified) agar in contrast with PY-O (oligofructose fortified) agar	54
4	Inhibitory activity of <i>B. pseudocatanulatum</i> F117 and JCM 1200 against <i>E. coli</i> V157 on (a) PY-O agar and (b) PY-I agar	60



# LISTS OF ABBREVIATIONS

ATP	:	adenosine triphosphate
ATCC	•	American Type Culture Collection
ca.	:	calculated
CFC	:	continuous flow culture
cfu	:	colony forming unit
conc.	:	concentration
d	:	day
D	:	dilution rate
DP	:	degree of polymerization
E. coli	:	Escherichia coli
ENDO	:	a European Commission-funded project on NDOs
e.g.	:	example gratia (for example)
et al.	:	et cetera (and company)
FOS	:	fructooligosaccharides
Fruc	:	fructose
g	:	gram
GALT	:	gut-associated lymphoid tissues
GF2	:	1-kestose
GIT	:	gastrointestinal tract
Glu	:	glucose
h	:	hour



h <sup>-1</sup>	:	per hour
H+	:	hydrogen ion
HCl	:	hydrochloric acid
HCO <sub>3</sub> -	•	hydrogen carbonate ion
H <sub>2</sub> SO <sub>4</sub>	•	sulphuric acid
i.e.	:	<i>id est</i> (that is)
JCM	:	Japan Collection of Microorganisms
L	:	liter
LAB	:	lactic acid bacteria
log	:	logarithm
М	:	molar
MCS	:	multiple chamber operation systems
mL	:	milliliter
mM	:	millimolar
n	:	number
Ν	:	normality
NaOH	:	sodium hydroxide
NDOs	:	non-digestible oligosaccharides
O <sub>2</sub>	:	oxygen
PY-G	:	peptone yeast glucose
PY-O	:	peptone yeast oligofructose



PY-I	:	peptone yeast inulin
R	:	resident time
rDNA	:	ribosomal deoxyribonucleic acid
rpm	•	revolution per minute
SCFA	:	short chain fatty acids
SCFAH	:	protonated short chain fatty acids
SOS	:	soybean oligosaccharides
spp	:	species
Th	:	T helper cells
TOS	:	transgalactosyl-oligosaccharides
TPY	:	trypticase-phytone-yeast extract
v	:	volume
XOS	:	xylo-oligosaccharides
μL	:	microliter
Δ	:	transmembrane pH gradient
α	:	alpha
β	:	beta
%	:	percentage
<sup>0</sup> C	•	degree Celsius
/	:	per
μ	:	specific growth rate
$\mu_{\rm m}$	:	maximum specific growth rate

xxi

#### **CHAPTER 1**

#### **INTRODUCTION**

Gut health is currently getting much attention among researchers and public. This is mainly because many of the physical health problems were found closely related to the improper functionality of gut. Over the years, study of the microbiological system in the gut has slowly uncovered the general effects brought to the host. Evolved from birth, this group of microorganism has adapted and changed according to the maturity of gut, which make them present as one entity in the so-called "symbiosis" relationship. This is the most important fact that many researchers have been neglecting so far, by putting less attention to the biochemistry of these microorganisms. These organisms and their metabolic activities are not inert to the human host and have both positive and negative impacts on health. The balance of this ecosystem is dynamic and may be altered by several factors such as aging, medication, stress, diet, and some other environmental factors (Conway, 2001). The maintenance of a community of bacteria, which contains a predominance of beneficial species and minimal putrefactive processes, is believed to be important for maintaining intestinal health.

The concept of probiotic appears when effort is made to modify or alter the composition of the microfloras in the gut to a remedial one by directly introducing the biologically important beneficial microorganism (Gibson and Roberfroid, 1995).



Most of the attempt microorganisms are of human origin and largely represented by *Bifidobacterium* and *Lactobacilli* (Silvi *et al.*, 2003). These microorganisms are found to be the predominant gut floras in the breastfed infants and also in healthy adults. The beneficial influences of probiotic on human gut floras include factors such as antagonistic effects, competition and immune effects. Improved resistance to pathogen offers the most promise for development of efficacious probiotics. The use of probiotic bacterial cultures stimulates the growth of preferred microorganism, crowds out potentially harmful bacteria and reinforces the body's natural defense mechanisms (Conway, 2001).

Currently, the prebiotic strategy is proposed as an alternative mode to improve the well being of gut. This is the application of indigestible food ingredient that has impact on the metabolism of intestinal microorganisms (Holzapfel and Schillinger, 2002). In the scientific literature, most of the data on prebiotic effect deals with inulin and fructooligosaccharides, and a range of commercial products have been available for many years. First the majority of data were produced on the ability of these carbohydrates to increase the amount of bifidobacteria in faeces. During recent years, more emphasis has been put on physiological functions, such as gut function, colon cancer biomarkers, calcium absorption and lipid metabolism (Puupponen-Pimia *et al.*, 2002).

Due to the potential synergy between probiotic and prebiotic, foods containing a combination of these ingredients are often referred to as synbiotic

(Gibson and Roberfroid, 1995). Prebiotic might influence the growth and survival of the probiotic and starter in fermented dairy products. One may also expect the prebiotic to serve as a preliminary growth substance while introducing a biologically important probiotic into the gut. This is especially important in view of the weakness of probiotic surviving through gastrointestinal tract to reach an allocated site such as in the small and large bowel. Nonetheless, endeavors have been made to improve the competency of the probiotic consumed. Some researchers suggested having preadaptation of the probiotic to prebiotic prior to consumption. This might post competitive advantage for the probiotic if it is consumed concurrently with the prebiotic (Conway, 2001). On the other hand, the correct pair of probiotic and prebiotic is designed to ensure a successful establishment of probiotic in the gut among the presence of the large microbial assemblage (Fooks and Gibson, 2002). This is true when the substrate affinity of probiotic, for example Bifidobacterium, is varied among species and strains. Therefore, in applying the principle of synbiotic, besides proper strains selection for a characteristic probiotic, one has to take into consideration the substrate affinity of these probiotic as well. Therefore, current research is trying to focus on several topics regarding the application of synbiotic in vitro as below:

 To compare substrate affinity of 8 locally isolated wild type *Bifidobacterium* pseudocatenulatum and 4 commercial *Bifidobacterium* spp. towards oligofructose and inulin,

